Tekla Life Sciences Investors
HQL · NYSE
3/31/2025 | 9/30/2024 | 3/31/2024 | 9/30/2023 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 850.5% | -7.3% | -93% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 0% | 100% | 100% | 91.2% |
| EBITDA | -$0 | $0 | $0 | -$0 |
| % Margin | -259.5% | 0% | 4,898.5% | -38.7% |
| Net Income | -$0 | $0 | $0 | -$0 |
| % Margin | -259.5% | 1,830% | 2,433.4% | -38.7% |
| EPS Diluted | -1.64 | 1.22 | 1.84 | -0.43 |
| % Growth | -234.4% | -33.7% | 527.9% | – |
| Operating Cash Flow | -$0 | – | – | $0 |
| Capital Expenditures | -$0 | – | – | $0 |
| Free Cash Flow | -$0 | – | – | $0 |